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Abstract The purpose of this study was to analyze glu-
tathione antioxidant defense system in elderly patients
treated for hypertension. Studies were carried out in the
blood collected from 18 hypertensive and 15 age- and sex-
matched controls, all subjects age over 60. Hypertensives
were on their usual antihypertensive treatment at the time
of blood collection. The concentration of glutathione
(GSH) in whole blood and activities of glutathione per-
oxidase (GPx-1), glutathione transferase (GST), and glu-
tathione reductase (GR) in erythrocytes were measured.
The data from patients and controls were compared using
independent-samples t test. P value of 0.05 and less was
considered statistically signiﬁcant. We observed increased
glutathione-related antioxidant defense in treated hyper-
tensive elderly patients (HT) when compared with healthy
controls (C). Mean GSH concentration was signiﬁcantly
higher in HT when compared with C: 3.1 ± 0.29 and
2.6 ± 0.25 mmol/L, respectively, P\0.001. Mean activ-
ity of GR was signiﬁcantly higher in HT group if compared
with C: 83.4 ± 15.25 U/g Hb versus 64.2 ± 8.26 U/g Hb,
respectively, P\0.001. Mean activity of GST was sig-
niﬁcantly higher in HT group compared with C: 3.0 ±
0.60 mmol CDNB-GSH/mgHb/min and 2.6 ± 0.36 mmol
CDNB-GSH/mgHb/min, respectively, P\0.05. No dif-
ference in GPx activity was observed between two groups.
These results show that glutathione-related antioxidant
defense system was enhanced in elderly hypertensive
patients treated for their conditions. This suggests important
role of glutathione system in blood pressure regulation.
Alterations in concentration and activity of antioxidants
observedduringantihypertensivemedicationarelikelytobe
related to the effect of the treatment on NO bioavailability.
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Introduction
Hypertension is highly prevalent risk factors for cardio-
vascular disease morbidity and mortality in elderly and can
affect as much as 70% older adults [1]. Although hyper-
tension is a complex trait, which involves multiple and
complex pathways, the association with oxidative and
nitrosative stress has been shown for hypertension, with the
evidence of NAD(P)H oxidase and uncoupled nitric oxide
synthase as a major sources of reactive oxygen species
(ROS) [2, 3].
Elevated ROS formation in the vascular wall is a key
feature of cardiovascular diseases and contributes to
endothelial dysfunction and vascular inﬂammation [4, 5]. It
has been shown that induced hypertension, cardiac hyper-
trophy, and impaired vascular relaxation are associated
with increased superoxide radical.
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quence of a primary decrease in the antioxidant defense
system activity or an elevation of ROS concentration [6, 7].
Many studies indicate that O2
-,H 2O2, and peroxynitrite
(ONOO
-), which is formed in radical–radical coupling
reactions, play an important role in the development of
hypertension due to their effect on vascular tone [8]. The
relation between increased ROS production and high blood
pressure has been explained through enhanced inactivation
of the vasodilator nitric oxide (NO) by superoxide radical
(O2
-)[ 9, 10]. Vascular NADP(H) oxidases, a major source
of vascular ROS production, contribute to regulation of
vascular tone [11]. Under physiological conditions, ROS
formation by oxidant enzymes and ROS elimination by
antioxidant enzymes are balanced in vascular wall.
Although there is evidence for association of blood
pressure with oxidative stress, which suggests a possible
role of oxidative stress in endothelial dysfunction and
pathophysiology of essential hypertension, the relationship
between blood pressure and oxidative stress parameters is
still not clear [7, 9]. Therefore, more studies aiming to
identify free radicals and their intermediates as well as
evaluate the traces of radical attack on biological mole-
cules and estimate antioxidant status in hypertension are
required. We have hypothesized that cellular glutathione
antioxidant defense system is involved in blood pressure
regulation.
There are many physiological processes in the human
body, which generate reactive oxygen species. ROS are
unstable and highly reactive chemical molecules. The
univalent reduction of oxygen in mitochondria leads to
superoxide radical (O2
-). Afterward hydrogen peroxide
(H2O2) and hydroxyl radical (OH
) are produced. Other
types of free radicals are nitric oxide radical (NO
), per-
oxynitrite (ONOO
-), and lipid peroxyl radical (LOO
).
When production of oxidants overwhelms the cellular
antioxidant capacity, the state of oxidative stress occurs,
resulting in molecular and cellular tissue damage and
severe metabolic malfunctions caused by oxygen radical–
mediated toxicity. Speciﬁc enzymes and low molecular
weight substances eliminate reactive oxygen species and
contribute to the redox balance in the cell.
Glutathione serves as a major thiol-disulﬁde redox
buffer for the cell. GSH synthesis is catalyzed by c-glut-
amyl cysteine synthetase (c-GCS) and GSH synthetase.
Transcription and activity of c-GCS is regulated by many
factors and processes such as GSH depletion, GSH con-
jugation, antioxidants, inﬂammatory cytokines, nitrosative
stress, and oxidative stress [12]. Oxidative stress is asso-
ciated with GSH oxidation and depletion, which has been
observed in hypertensive subjects when compared with
non-hypertensive individuals [7, 13, 14]. GSH is utilized as
a cofactor by cellular glutathione peroxidase (Gpx-1) to
reduce H2O2 and organic hydroperoxides. The overall
reaction reduces one peroxide molecule to two waters and
oxidatively couples two glutathione molecules liberating
oxidized glutathione—glutathione disulﬁde (GSSG) [15].
Glutathione transferase (GST) is a part of a phase 2
detoxiﬁcation and catalyzes deactivation of many harmful
substances and also requires for these reactions reduced
glutathione (GSH) as a cofactor [16]. Since many meta-
bolic pathways result in decrease in GSH and an increase in
GSSG concentrations, the restoration of reduced glutathi-
one is crucial for the glutathione redox metabolism.
Glutathione reductase (GR), catalyzing the reaction
NADPH ? GSSG ? H(?) ? NADP(?) ? 2 GSH, plays
an important role in the maintenance of the cell oxidant
status [17]. The erythrocyte metabolism of glutathione is
essential not only for redox balance but also nitric oxide
bioavailability in erythrocytes; hence, it may contribute to
the prevalence of hypertension [18].
It has been shown that hypertension is associated with
disturbances in glutathione metabolism. Mononuclear cells
from hypertensive subjects display signiﬁcantly lower GSH
and higher GSSG values than from the control group [19].
Furthermore, activity of enzymes involved in glutathione
metabolism is also disturbed in hypertension since decrease
in activities of c-GCS, GR, and GPx have been reported
[19, 20]. Decreased activity of antioxidant enzymes in
hypertension has been explained by impaired enzyme
expression response and enzyme inactivation in the con-
ditions of oxidative stress [19]. It has been also demon-
strated that antihypertensive treatment reduces oxidative
stress [9, 21] and results in the increase in GSH level and
decrease in GSSG and signiﬁcant enhancement of enzymes
involved in glutathione metabolism [19, 22].
Furthermore, it has been also established that aging
is associated with disturbances in glutathione metabo-
lism [23, 24]. Different studies have demonstrated both
decreased [25] and increased [26] as well as unaltered [27]
level of glutathione with age. Regarding GPx activity,
results are also contradictory, and we still cannot inter-
changeably conclude whether the activity of GPx decreases
[27] or increases [28] with age. Age-related disturbances in
glutathione reductase activity have been also reported [28,
29]. Besides, frequency of homozygotes for glutathione
transferase GSTT1 deletion increases with age [30]. Epi-
demiological studies have shown that advancing age is
associated with an increased prevalence of hypertension
[31] and genetic effect on blood pressure is modulated by
age [32].
Altogether, this evidence suggests that oxidative stress,
and in particular, disturbed glutathione metabolism is
related to pathogenesis of hypertension. The purpose of this
study was to analyze glutathione antioxidant defense sys-
tem in elderly patients treated for hypertension. The
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123concentration of glutathione (GSH) and activities of
glutathione peroxidase (GPx-1), glutathione S-transferase
(GST), and glutathione reductase (GR) were measured.
Methods
Subjects
Eighteen elderly hypertensive patients and 15 age- and sex-
matched healthy elderly controls were recruited to the
Department of Gerontology and Clinic of Geriatrics,
Nicolaus Copernicus University Collegium Medicum in
Bydgoszcz.Allsubjectswereevaluatedbystandardphysical
examination and routine clinical laboratory tests. Table 1
showstheclinicalcharacteristicsofthecontrolsandpatients.
The hypertension group (HT) consisted of 12 females
and 6 males, mean age 82.6 ± 7.52. Patients included to
this group had been already diagnosed for hypertension
andhadbeentreatedfortheirconditionsforatleast6months
before they were included in the study. We considered suc-
cessfully treated hypertensives with blood pressure below
140/90 mmHg (Table 2). Hypertensives were on their usual
antihypertensive medication at the time of blood collection.
We decided not to withdraw patients from their usual med-
ication for the ethical reasons, with advanced age being the
most important concern and risk factor for possible com-
plications, associated with treatment alterations. Seven
hypertensives were treated with combination of statins,
b-blockers, and ACE inhibitors, 5 patients were treated with
combinations of statins and b-blockers, 4 patients were
treated with combinations of statins and ACE inhibitors,
1 patient was treated with combination of b-blocker and
ACE-inhibitor, and 1 patient was treated with sartan only.
Exclusion criteria for this group were plasma glucose
C6 mmol/L, cancer, dementia, Alzheimer disease, antiox-
idants supplementation, smoking, and alcohol abuse.
The control group consisted of 12 females and 3 males,
mean age 76.5 ± 9.56. Exclusion criteria for this group
were hypertension, plasma glucose C6 mmol/L, cancer,
dementia, Alzheimer disease, antioxidants supplementa-
tion, smoking, and alcohol abuse.
The study was approved by the Nicolaus Copernicus
University in Torun ´ Human Ethics Committee. Written
informed consent was obtained before inclusion in the
study.
Blood Samples
Venous EDTA anticoagulated fasting blood samples were
collected in the morning (08:00 am). GSH concentration
was determined spectrophotometrically in the whole blood,
method described by Beutler. Remaining blood was cen-
trifuged (2,500g for 10 min), and after careful removal of
plasma and buffy coat, the red blood cells were washed
with cold isotonic saline (0.89% NaCl, pH = 7.4). The
hemolysate was prepared by threefold freezing and thaw-
ing the washed erythrocytes, suspended in bidistilled water.
GPx-1, GST, and GR activities were determined in eryth-
rocytes from hemolyzed blood samples according to Paglia
and Valentine [33], Habig [34], and Flohe and Gunzler [35]
methods, respectively.
Statistical Analysis
We have tested the null hypothesis that the mean values of
analyzed parameters were not different between hyperten-
sive patients and healthy controls. The values of oxidative
stress parameters were expressed as mean ± S.D. Compar-
isons were made using independent-samples t test between
groups since all variables were continuous and displayed
normal distribution. GSH, GPx, GR, and GST association
with age, sex, BMI, systolic and diastolic blood pressure,
plasma glucose, plasma HDL and LDL cholesterol,
Table 1 Clinical characteristics of the subjects included in the study
Parameters Healthy elderly controls Elderly hypertensive patients
Number of subjects 15 18
Age (year) 76.5 ± 9.56 82.6 ± 7.52
Smoking (yes/no) NO NO
Body mass index (kg/m
2) 26.9 ± 4.91 28.2 ± 4.88
Systolic blood pressure (mmHg) 130.7 ± 13.56 129.4 ± 7.37
Diastolic blood pressure (mmHg) 76.9 ± 10.42 70.6 ± 11.80
Plasma glucose (mmol/L) 5.27 ± 0.42 5.07 ± 0.64
Plasma HDL cholesterol (mmol/L) 1.2 ± 0.22 1.2 ± 0.31
Plasma LDL cholesterol (mmol/L) 2.2 ± 0.88 2.4 ± 0.40
Triglycerides (mmol/L) 1.6 ± 0.72 1.8 ± 0.68
Values are expressed as mean ± SD. There were no statistically signiﬁcant differences between groups; P\0.05 was considered statistically
signiﬁcant
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using regression analysis. None of these clinical character-
istics had signiﬁcant effect on analyzed parameters. Statis-
tica version 9 software was used for statistical analysis.
Differences were considered signiﬁcant if the two-sided
P value was 0.05 or less.
Results
In order to examine glutathione antioxidant defense system
in elderly patients treated for hypertension, we analyzed
concentration of glutathione (GSH) and activities of the
main antioxidant enzymes involved in metabolism of glu-
tathione i.e., glutathione peroxidase (GPx), glutathione
transferase (GST), and glutathione reductase (GR).
The glutathione metabolism was considerably changed
in elderly hypertensive patients compared with healthy
controls. We observed signiﬁcantly increased level
(P\0.01) of GSH glutathione in patients with treated
hypertension if compared with healthy individuals. The
levels of glutathione expressed by hypertensives and con-
trols were 3.1 ± 0.29 and 2.6 ± 0.25 mmol/L, respec-
tively (Fig. 1; Table 2).
We also investigated a possible association of the
change in GSH level with the activity of enzymes, which
Table 2 Parameter values of patients and controls
Group Gender Age BMI Systolic
blood pressure
[mmHg]
Diastolic
blood pressure
[mmHg]
GSH
[mmol/L]
GPx
[U/gHb]
GR
[U/gHb]
GST [mmol
CDNB-GSH/
mgHb/min]
MDA
[mmol/gHb]
Hypertension Female 82 33 129 79 2.6 10.8 110.7 2.9 0.203
Hypertension Female 86 24 130 49 3.0 13.8 101.8 3.7 0.204
Hypertension Female 79 25 119 71 3.3 16.5 71.0 4.1 0.248
Hypertension Female 88 32 136 76 2.8 14.2 96.0 2.3 0.230
Hypertension Male 84 27 139 87 3.0 12.7 83.6 2.5 0.228
Hypertension Female 84 26 131 62 3.6 12.1 99.1 2.5 0.289
Hypertension Male 66 31 120 59 3.5 13.6 82.6 2.2 0.231
Hypertension Female 91 24 136 70 3.2 13.4 71.5 2.7 0.184
Hypertension Female 86 33 139 64 3.2 14.9 105.9 2.3 0.181
Hypertension Female 89 28 121 54 2.8 17.3 82.2 2.5 0.174
Hypertension Male 80 15 121 81 3.0 14.8 82.0 3.6 0.228
Hypertension Male 75 26 138 89 3.0 12.7 73.6 2.9 0.249
Hypertension Female 35 122 69 3.0 11.0 87.5 3.7 0.133
Hypertension Male 74 34 133 85 3.5 10.9 71.0 3.5 0.185
Hypertension Female 83 32 138 66 3.0 14.2 68.1 3.1 0.195
Hypertension Female 93 29 121 56 2.7 11.0 57.9 3.5 0.209
Hypertension Female 92 25 132 81 3.5 12.0 93.8 3.8 0.254
Hypertension Male 72 29 125 73 3.1 10.9 63.4 3.0 0.241
Control Female 68 27 109 78 2.1 16.7 64.6 2.0 0.305
Control Female 66 23 108 78 2.7 12.6 84.1 2.4 0.300
Control Female 77 28 153 79 2.6 16.7 64.5 2.6 0.280
Control Female 66 27 145 75 2.8 14.1 74.1 2.9 0.310
Control Female 78 15 118 70 2.3 17.0 53.0 3.0 0.255
Control Male 66 32 122 99 3.0 13.6 62.1 2.3 0.280
Control Female 74 29 143 60 2.8 12.5 62.1 2.2 0.300
Control Female 74 25 137 64 2.7 16.0 53.1 3.1 0.280
Control Female 82 31 128 82 2.8 10.1 56.9 2.8 0.265
Control Female 85 37 129 78 3.0 12.1 71.7 3.1 0.290
Control Female 89 23 129 81 2.4 10.5 59.5 2.9 0.265
Control Male 91 25 120 71 2.7 16.0 70.1 2.3 0.220
Control Female 83 27 134 65 2.6 9.0 58.2 2.5 0.290
Control Female 87 25 146 94 2.5 10.1 65.0 2.2 0.270
Control Male 61 29 140 80 2.5 11.4 63.3 2.4 0.240
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123use GSH as a cofactor for their antioxidant and detoxiﬁ-
cation capacity. Glutathione peroxidase (GPx), which
inactivates peroxides, was unchanged in patients and met
the values observed in the controls with the activities of
13.2 ± 1.95 U/g Hb and 13.2 ± 2.74 U/g Hb, respectively
(Fig. 2; Table 2). We also looked at correlation between
GPx activity and GSH concentration. Although no signif-
icant interconnections were revealed, the controls exhibited
medium negative association (Pearson product-moment
correlation coefﬁcient r =- 0.47). When Pearson product-
moment correlation coefﬁcient between GPx and GSH was
determined for the hypertension group, we received value
of r =- 0.04 indicating no association at all.
Unlike GPx, GST activity signiﬁcantly differed between
groups (P\0.05) and was higher in hypertensives than
in controls: 3.0 ± 0.60 mmol CDNB-GSH/mgHb/min and
2.6 ± 0.36 mmol CDNB-GSH/mgHb/min, respectively
(Fig. 3;Table2).RegardingcorrelationbetweenGSTactivity
and GSH level, again no signiﬁcant association was detected.
Finally, we addressed the question whether the altera-
tions observed in glutathione concentration were related to
the change in GR activity. We assumed that elevated level
of glutathione is the result of increased activity of GR.
Indeed, activity of GR was signiﬁcantly higher (P\0.001)
in patients treated for hypertension than in age- and sex-
matched controls with the values of 83.4 ± 15.25 U/g Hb
and 64.2 ± 8.26 U/g Hb, respectively (Fig. 4; Table 2).
However, hypertension group displayed higher activity
of the enzyme and consequently higher concentration of
GSH, these parameters were not signiﬁcantly correlated in
our study. Interestingly, when looked at the correlation
between GR activity and GSH concentration in each group
separately, we observed there was a slightly positive
correlation between these two parameters in the healthy
control population (Pearson product-moment correlation
coefﬁcient r = 0.28). When Pearson product-moment
correlation coefﬁcient between GR and GSH was deter-
mined for the hypertension group, we received value of
r =- 0.02 indicating lack of any interrelation between
these parameters.
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Fig. 1 Mean GSH concentration in hypertensive subjects compared
with controls. Independent-samples t test
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Fig. 2 Mean GPx activity in hypertensive subjects compared with
controls. Independent-samples t test
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Fig. 3 Mean GST activity in hypertensive subjects compared with
controls. Independent-samples t test
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123Discussion
Our results suggest disturbances in glutathione-related
antioxidant defense system in elderly hypertensive patients
since we have observed changes in glutathione concentra-
tion and in the activity of glutathione transferase (GST) and
glutathione reductase (GR). However, concentration of
glutathione and activities of GST and GR were signiﬁ-
cantly higher in elderly patients treated for hypertension,
and GPx-1 had the same activity in hypertensives and
controls. Further evidence for the association between
glutathione system malfunctions and hypertension was
absolute lack of correlations between glutathione concen-
tration and activity of its enzymes in hypertension group.
Positive association between GSH and GR and negative
association between GSH and GPx were observed only in
controls. Since GPx-1 utilizes GSH for the action against
peroxides, increased activity of the enzyme caused
decrease in GSH concentration. GR is the enzyme that
restores GSH from oxidized disulﬁde GSSG form and that
explains why increase in the enzyme activity positively
corresponded with GSH level.
The data from our research suggest signiﬁcantly
increased level of glutathione (GSH) in treated hypertensive
elderly subjects when compared with non-hypertensive
group at similar age. Signiﬁcantly increased concentration
of antioxidant glutathione in patients who were successfully
treated for hypertension implies that antihypertensive
treatment improved antioxidant defense. In fact, antihy-
pertensive drugs are proven to have antioxidant properties
and the ability to lower oxidative stress [7, 9, 22, 36, 37]. On
the other hand, we cannot assume that increased level of
glutathione is tantamount to decreased oxidative stress,
since high level of GSH can be also seen as an adaptive
mechanism to oxidative stress, as the latter induces the
endogenous antioxidant such as GSH. Furthermore, the
GSH can be also accumulated in erythrocytes when it is
poorly utilized by the cells.
Accumulation of GSH in patients could be due to the
reduction in the activity of GPx and concomitant increase
in GR activity, since both were observed herein. But why
GPx activity did not follow the trend of the other enzymes,
which signiﬁcantly increased in activity in hypertensives?
Curiously, it has been shown that GPx can be inactivated in
the conditions of oxidative stress as superoxide radical
(O2
-) can inhibits peroxide function of the enzyme [38]. It
could be a case especially that O2
- is believed to play
major role in hypertension pathology. But on the other
hand, we should expect decreased level of superoxide
throughout antihypertensive treatment. It should also be
taken into consideration that, however, protective role of
GPx in coping with oxidative injury and cell death medi-
ated by reactive oxygen species in vivo has been supported
by substantial body of evidence, the ability to potentiate
reactive nitrogen species (RNS), has been also reported.
GPx seems to play contradictory roles in coping with ROS
versus RNS [39]. No alterations in GPx activity in hyper-
tensive subjects observed in our study could be a one of the
actions to prevent nitrate stress and to maintain lower blood
pressure.
One of the mechanisms that links antioxidant and anti-
hypertensive properties can be decreased level of super-
oxide radical O2
- under antihypertensive treatment. This
effect can be mediated by increased level of glutathione
which is known to prevent PDGF-mediated production of
reactive oxygen species by NADH/NADPH oxidase, which
is considered to be the main source of vascular ROS and
O2
- in particular [6, 9, 11, 22, 40]. Moreover, GSH in
reaction with peroxynitrite ONOO
- forms S-nitrosothiols,
which have the ability to inhibit NADPH oxidase [41].
Furthermore, S-nitrosothiols subsequently release NO over
prolonged time, thus extend the half-life of NO many-fold
and in consequence relax vascular tissue [42–44].
In order to analyze glutathione antioxidant defense
system in elderly patients treated for hypertension, we also
measured activities of glutathione peroxidase (GPx), glu-
tathione transferase (GST), and glutathione reductase (GR).
Concerning GR activity, it was signiﬁcantly higher in
hypertensive patients than in controls. Altogether our
results suggest high turnover and oxidation of GSH. Oxi-
dized form of glutathione (GSSG) is the substrate for GR,
which restores glutathione in reduced state [12, 45]. Nev-
ertheless, in our study, the relation between GSH concen-
tration and GR activity was not as elegant as expected,
namely these two parameters were not signiﬁcantly
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Fig. 4 Mean GR activity in hypertensive subjects compared with
controls. Independent-samples t test
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123correlated. However, medium positive correlation was seen
in controls, hypertensives perfectly showed no correlation.
It can suggest hypertension-related disturbances in gluta-
thione system, which went haywire in patients when
compared with controls.
Results from our research allow us to some extent
answer the question what for GSH was intensively used in
hypertensives, since we analyzed activity of enzymes for
which GSH serves as a cofactor. Interestingly, we observed
no difference between controls and hypertension group in
the activity of GPx. With regard to hypertension important
functions of GPx are reduction in peroxides that has been
reported to inactivate vasodilator NO [46] and decompo-
sition of GSNO [47] that play essential role in vascular
homeostasis.
For GSNO decomposition in the context of GPx activity,
no arbitrary conclusion can be made since the process is
complexandcanalsoinvolveafewotherdenitrosylases[47–
51]. Toward inactivation of peroxides, likewise GPx shares
its function with other enzyme i.e., glutathione transferase
(GST), which role in cellular protection of the erythrocytes
against oxidative damage has been apprised [52]. In our
study, we noticed signiﬁcant increase in the activity of GST
in treated hypertensive if compared with controls.
GST catalyzes conjugation of GSH with various elec-
trophiles, physiological metabolites, and xenobiotics. The
important role of GST is detoxiﬁcation of ROS and limi-
tation of oxidative damage to the tissues [12, 53–55].
Hypertension is associated with decreased activity of many
antioxidant enzymes including GST [56]. Increased GST
activity can result in higher GSH demand for conjugation
reactions. Further, conjugation regulates synthesis of GSH
by increase in c-GCS transcription [12] and that is why we
looked for association between these parameters. Still, we
would like to emphasize the fact that GST activity and
GSH concentration were not correlated in our study, and
the efﬂux of conjugates in erythrocytes from hypertensive
subjects was not measured. Therefore, the hypothesis that
antihypertensive treatment enhances detoxifying capacity
by inducing GSTs and modifying GST genotype should be
taken into consideration, but more research is required to
elucidate this association.
GST is a family of isoenzymes from several classes
(alpha, kappa, mu, omega, pi, theta) located in cytosol,
mitochondria, and microsomes. When the enzymatic
activity of total GST is determined by CDNB, h-GST
seems to be the highest among GST izoenzymes charac-
terized so far from human tissues. h-GST has been sug-
gested to be functional in the removal of circulating
xenobiotic [57]. h-GST expression is associated with
GSTT1 genotype. GSTT1 has 2 alleles, denoted GSTT1*0
for the non-functional allele and GSTT1*1 for the func-
tional allele [58]. GSTT1-positive carriers display higher
GST activity and may be protected against oxidative stress
and oxidative DNA damage [59]. The association between
GSTT1 and hypertension has been established, although the
data are not consistent [13, 54, 60]. GSTM1*0/GSTT1*0
genotype has been identiﬁed as a potential genetic risk
factor to predict development of essential hypertension
[61, 62].
Altogether results of our research suggest that glutathi-
one antioxidant defense system in elderly patients treated
for hypertension is changed as signiﬁcantly higher GSH
concentration and activity of GST as well as GR were
observed. Consistently, we provide more evidence that
oxidative stress plays important role in hypertension
pathogenesis. A limitation of this study is the lack of
measurement of ROS and/or their by-products, as well as
assessment of only selected antioxidants which allows only
for speculations and indirect conclusions about oxidative
stress. Our results show that glutathione-related antioxidant
defense system was enhanced in elderly hypertensive
patients treated for their condition. There is important
question to be addressed, whether increase in glutathione-
related antioxidant defense system was a result of antiox-
idant effect of the antihypertensive medication or a com-
pensation mechanism for increased ROS generation due to
the disease state. Since we saw decreased level of lipid
peroxidation measured as a concentration of malondialde-
hyde in patients when compared with controls (data not
shown), we believe that higher GSH concentration as well
as activities of GST and GR was more likely caused by
antioxidant properties of the antihypertensives. Alterations
in concentration and activity of antioxidants observed
during antihypertensive medication could be related to the
effect of the treatment on NO bioavailability.
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